The glucose-dependent T2D therapies such as glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 inhibitors, promote glucose control by minimizing both hyperglycaemia and hypoglycaemia. The gene discussed is GLP1R; the disease is Hypoglycemia.